Literature DB >> 34124779

Chronic viral hepatitis, HIV infection and Non-Hodgkin lymphomas in West Africa, a case-control study.

Antoine Jaquet1, Simon P Boni2,3, Kouakou Boidy4, Judicaël Tine5, Boris Tchounga3,6, Sokhna A Touré7, Jean-Jacques Koffi3, Cherif Dial8, Alain Monnereau1, Isidore Diomande9, Aristophane Tanon10, Moussa Seydi5, François Dabis1, Saliou Diop7, Gustave Koffi4.   

Abstract

Non-Hodgkin lymphomas (NHL) are underestimated causes of cancer in West Africa where chronic viral hepatitis and HIV are endemic. While the association with HIV infection has already been characterized, limited information is available on the association between chronic viral hepatitis and NHL in sub-Saharan Africa. A case-control study was conducted in referral hospitals of Abidjan (Cote d'Ivoire) and Dakar (Senegal). Cases of NHL were matched with controls on age, gender and participating site. The diagnosis of NHL relied on local pathological examination completed with immunohistochemistry. HIV, HBV and HCV serology tests were systematically performed. A conditional logistic regression model estimated the associations by the Odds Ratio (OR) with their 95% confidence interval (CI). A total of 117 NHL cases (Abidjan n = 97, Dakar n = 20) and their 234 matched controls were enrolled. Cases were predominantly men (68.4%) and had a median age of 50 years (IQR 37-57). While Diffuse Large B-cell lymphoma were the most reported morphological type (n = 35) among mature B-cell NHL, the proportion mature T-cell NHL (30%) was high. The prevalence figures of HBV, HCV and HIV infection were 12.8%, 7.7% and 14.5%, respectively among cases of NHL. In multivariate analysis, HBV, HCV and HIV were independently associated with NHL with OR of 2.23 (CI 1.05-4.75), 4.82 (CI 1.52-15.29) and 3.32 (CI 1.54-7.16), respectively. Chronic viral hepatitis B and C were significantly associated with NHL in West Africa. Timely preventive measures against HBV infection and access to curative anti-HCV treatment might prevent a significant number of NHL.
© 2021 UICC.

Entities:  

Keywords:  Africa; HBV; HCV; HIV/AIDS; epidemiology; non-Hodgkin lymphoma

Mesh:

Year:  2021        PMID: 34124779      PMCID: PMC8486336          DOI: 10.1002/ijc.33709

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  32 in total

1.  Characterization of hepatitis B virus infection and viral DNA integration in non-Hodgkin lymphoma.

Authors:  Mengge Li; Yuling Shen; Yiming Chen; Haifeng Gao; Jiaqin Zhou; Qing Wang; Chunsun Fan; Wei Zhang; Jin Li; Hui Cong; Jinyang Gu; Yu Gan; Hong Tu
Journal:  Int J Cancer       Date:  2020-05-09       Impact factor: 7.396

2.  Accurate Real-Time Diagnosis of Lymphoproliferative Disorders in Malawi Through Clinicopathologic Teleconferences:  A Model for Pathology Services in Sub-Saharan Africa.

Authors:  Nathan D Montgomery; N George Liomba; Coxcilly Kampani; Robert Krysiak; Christopher C Stanley; Tamiwe Tomoka; Steve Kamiza; Bal M Dhungel; Satish Gopal; Yuri Fedoriw
Journal:  Am J Clin Pathol       Date:  2016-09-04       Impact factor: 2.493

3.  Non-Hodgkin lymphoma in Southern Africa: review of 487 cases from The International Non-Hodgkin Lymphoma Classification Project.

Authors:  Anamarija M Perry; Yvonne Perner; Jacques Diebold; Bharat N Nathwani; Kenneth A MacLennan; Hans K Müller-Hermelink; Martin Bast; Eugene Boilesen; James O Armitage; Dennis D Weisenburger
Journal:  Br J Haematol       Date:  2015-12-21       Impact factor: 6.998

4.  Can we reduce the incidence of adult T-cell leukaemia/lymphoma? Cost-effectiveness of human T-lymphotropic virus type 1 (HTLV-1) antenatal screening in the United Kingdom.

Authors:  Bassit Malik; Graham P Taylor
Journal:  Br J Haematol       Date:  2018-04-20       Impact factor: 6.998

5.  InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions.

Authors:  Jennifer J Turner; Lindsay M Morton; Martha S Linet; Christina A Clarke; Marshall E Kadin; Claire M Vajdic; Alain Monnereau; Marc Maynadié; Brian C-H Chiu; Rafael Marcos-Gragera; Adele Seniori Costantini; James R Cerhan; Dennis D Weisenburger
Journal:  Blood       Date:  2010-08-10       Impact factor: 22.113

Review 6.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.

Authors:  Aparna Schweitzer; Johannes Horn; Rafael T Mikolajczyk; Gérard Krause; Jördis J Ott
Journal:  Lancet       Date:  2015-07-28       Impact factor: 79.321

7.  Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study.

Authors:  Raúl U Hernández-Ramírez; Li Qin; Haiqun Lin; Wendy Leyden; Romain S Neugebauer; Keri N Althoff; Chad J Achenbach; Nancy A Hessol; Gypsyamber D'Souza; Kelly A Gebo; M John Gill; Surbhi Grover; Michael A Horberg; Jun Li; W Christopher Mathews; Angel M Mayor; Lesley S Park; Charles S Rabkin; Kate Salters; Amy C Justice; Richard D Moore; Eric A Engels; Michael J Silverberg; Robert Dubrow
Journal:  Lancet HIV       Date:  2019-02-27       Impact factor: 16.070

8.  The burden of cancers associated with HIV in the South African public health sector, 2004-2014: a record linkage study.

Authors:  Tafadzwa Dhokotera; Julia Bohlius; Adrian Spoerri; Matthias Egger; Jabulani Ncayiyana; Victor Olago; Elvira Singh; Mazvita Sengayi
Journal:  Infect Agent Cancer       Date:  2019-05-03       Impact factor: 2.965

9.  Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa.

Authors:  Takondwa Zuze; Grace K Ellis; Edwards Kasonkanji; Bongani Kaimila; Richard Nyasosela; Ruth Nyirenda; Tamiwe Tomoka; Maurice Mulenga; Maria Chikasema; Blessings Tewete; Asekanadziwa Mtangwanika; Sarah Chiyoyola; Fred Chimzimu; Coxcilly Kampani; Wilberforce Mhango; Simon Nicholas; Cara Randall; Nathan D Montgomery; George Fedoriw; Katherine D Westmoreland; Matthew S Painschab; Satish Gopal
Journal:  Cancer Med       Date:  2019-11-09       Impact factor: 4.452

10.  Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus.

Authors:  Michael J Silverberg; Wendy Leyden; Raúl U Hernández-Ramírez; Li Qin; Haiqun Lin; Amy C Justice; Nancy A Hessol; Chad J Achenbach; Gypsyamber D'Souza; Eric A Engels; Keri N Althoff; Angel M Mayor; Timothy R Sterling; Mari M Kitahata; Ronald J Bosch; Michael S Saag; Charles S Rabkin; Michael A Horberg; M John Gill; Surbhi Grover; W Christopher Mathews; Jun Li; Heidi M Crane; Stephen J Gange; Bryan Lau; Richard D Moore; Robert Dubrow; Romain S Neugebauer
Journal:  Clin Infect Dis       Date:  2021-06-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.